Target intelligence / Profile preview

T-lymphocyte surface antigen Ly-9 (LY9)

Target
LY9
Molecular classification
Receptor
01

Overview

T-lymphocyte surface antigen Ly-9 (also known as CD229 or SLAMF3) is a type I transmembrane glycoprotein belonging to the signaling lymphocytic activation molecule (SLAM) family within the immunoglobulin superfamily. It is expressed on the surface of T and B lymphocytes, thymocytes, and natural killer (NK) cells, where it functions as a homophilic adhesion receptor and modulates immune cell activation, differentiation, and homeostasis. In healthy tissues, Ly-9 acts as a regulator of lymphocyte tolerance and development, but it is highly and stably overexpressed in hematological malignancies, particularly multiple myeloma and various B-cell lymphomas. Because of its uniform expression on malignant plasma cells and myeloma-propagating stem cells, Ly-9 has emerged as a highly promising therapeutic target. Current drug development efforts primarily focus on chimeric antigen receptor (CAR) T-cell therapies, including monospecific CD229 CAR-T cells and bicistronic constructs targeting both BCMA and CD229 to prevent antigen-escape relapses. Additionally, monoclonal antibodies targeting Ly-9 are being investigated for their ability to induce antibody-dependent and complement-dependent cytotoxicity in cancer, as well as for depleting pathogenic B-cell subsets in autoimmune conditions like Sjögren's syndrome.

Other names
CD229Lymphocyte antigen 9SLAM family member 3SLAMF3Signaling lymphocytic activation molecule 3Cell surface molecule Ly-9
02

Mechanism of action

Chimeric antigen receptor T-cell therapy, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and inhibition of homophilic interaction

03

Biological functions

Immune responseSignal transductionCell adhesion
04

Disease associations

CancerInflammationAutoimmune disease
05

Safety considerations

On-target off-tumor toxicityFratricide of CD229-positive healthy T cellsImmunosuppressionCytokine release syndrome (CRS)Neurotoxicity
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

CD229 expressionsCD229 (soluble CD229) levelsBCMA expression

Beyond the preview

Go deeper on T-lymphocyte surface antigen Ly-9 (LY9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-lymphocyte surface antigen Ly-9 (LY9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call